These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 3388475)
1. Comparative study of the efficacy and safety of intranasal DDAVP administered to normal blood donors. Palmer DS; Nair RC; Rock G Transfusion; 1988; 28(4):311-5. PubMed ID: 3388475 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness, specificity and safety of intranasal 1-deamino-8-D-arginine vasopressin treatment of normal blood donors. Palmer DS; Harris AS; Tittley P; Rock G Haemostasis; 1988; 18(3):187-96. PubMed ID: 2972594 [TBL] [Abstract][Full Text] [Related]
3. Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma. Konecka G; Bykowska K; Ludwicka A; Letowska M; Wegrzynowicz Z; Sablinski J; Lopaciuk S Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):565-70. PubMed ID: 1714861 [TBL] [Abstract][Full Text] [Related]
4. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis]. Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813 [TBL] [Abstract][Full Text] [Related]
5. [Subcutaneous administration of desmopressin to plasma donors: a controlled study]. Palacios S; Zuazu I; Candela MJ; Rivera J; Vicente V Med Clin (Barc); 1995 Oct; 105(14):525-7. PubMed ID: 8523926 [TBL] [Abstract][Full Text] [Related]
6. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor. Cattaneo M; Simoni L; Gringeri A; Mannucci PM Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023 [TBL] [Abstract][Full Text] [Related]
7. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Deitcher SR; Tuller J; Johnson JA Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955 [TBL] [Abstract][Full Text] [Related]
8. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII). Garcia VV; Silva IA; Borrasca AL Thromb Haemost; 1982 Aug; 48(1):91-3. PubMed ID: 6813999 [TBL] [Abstract][Full Text] [Related]
9. The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal persons. Nilsson IM; Mikaelsson M; Vilhardt H Scand J Haematol; 1982 Jul; 29(1):70-4. PubMed ID: 6812213 [TBL] [Abstract][Full Text] [Related]
10. Shortening of bleeding time after intranasal administration of 1-deamino-8-D-arginine vasopressin to patients with chronic uremia. Rydzewski A; Rowiński M; Myśliwiec M Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):823-30. PubMed ID: 2436997 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus. Lam KS; Wat MS; Choi KL; Ip TP; Pang RW; Kumana CR Br J Clin Pharmacol; 1996 Sep; 42(3):379-85. PubMed ID: 8877030 [TBL] [Abstract][Full Text] [Related]
12. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects. MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807 [TBL] [Abstract][Full Text] [Related]
13. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447 [TBL] [Abstract][Full Text] [Related]
14. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
16. Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of a vasopressin analogue. Mikaelsson M; Nilsson IM; Vilhardt H; Wiechel B Transfusion; 1982; 22(3):229-33. PubMed ID: 6806950 [TBL] [Abstract][Full Text] [Related]
17. 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor. Muhm M; Grois N; Kier P; Stümpflen A; Kyrle P; Pabinger I; Bettelheim P; Hinterberger W; Lechner K Haemostasis; 1990; 20(1):15-20. PubMed ID: 2108912 [TBL] [Abstract][Full Text] [Related]
18. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Lethagen S; Harris AS; Sjörin E; Nilsson IM Thromb Haemost; 1987 Dec; 58(4):1033-6. PubMed ID: 3127915 [TBL] [Abstract][Full Text] [Related]
19. Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. Vilhardt H; Lundin S Gen Pharmacol; 1986; 17(4):481-3. PubMed ID: 3758654 [TBL] [Abstract][Full Text] [Related]
20. Effect of 1-deamino-5-D-arginine vasopressin (DDAVP) on plasma cortisol (hydrocortisone). Rado JP; Juhos E J Clin Pharmacol; 1976 Jul; 16(7):333-7. PubMed ID: 985828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]